| Administration of tumor infiltrating lymphocytes with membrane bound interleukin 15 to treat cancer M Khattar, S Subramanian, R Burga, ML Ols, J Ter Meulen, K Pedro, ... US Patent App. 18/501,621, 2024 | | 2024 |
| Tumor-infiltrating lymphocytes with membrane bound interleukin 15 and uses thereof K Pedro, JA Storer, J Ter Meulen, R Burga, M Khattar, OLS Michelle, ... US Patent App. 18/261,765, 2024 | | 2024 |
| Compositions and methods for expansion of t cells and tumor infiltrating lymphocytes KG Elpek, C Richardson, ML Fleury, JA Storer, S Subramanian, M Khattar US Patent App. 18/261,761, 2024 | | 2024 |
| Enhancers of innate and adaptive immunity combine with membrane bound IL15 to increase the efficacy of tumor infiltrating lymphocyte (TIL) therapy for tumors with … C Passaro, B Koscso, S Smith, V Young, T Ross, B Primack, N Ly, ... J. Immunother. Cancer https://doi. org/10.1136/jitc-2022-sitc2022 369, 2022 | 2 | 2022 |
| Digital spatial profiling and antigen-dependent phenotypic analysis of IL15-engineered tumor-infiltrating lymphocytes (cytoTIL15 TM therapy) in an allogeneic melanoma PDX model R Burga, Z Ao, A Aksoy, S Lajoie, K Pedro, J Tremblay, G Kulkarni, ... Journal for ImmunoTherapy of Cancer 10, A411-A411, 2022 | | 2022 |
| Allogeneic, IL-2-independent tumor-infiltrating lymphocytes expressing membrane-bound IL-15 (cytoTIL15 (TM)) eradicate tumors in a melanoma PDX model through recognition of … JH Tchaicha, S Lajoie, R Burga, T Ross, B Primack, M Langley, V Young, ... CANCER RESEARCH 82 (12), 2022 | | 2022 |
| Abstract LB212: Allogeneic, IL-2-independent tumor-infiltrating lymphocytes expressing membrane-bound IL-15 (cytoTIL15࣪) eradicate tumors in a melanoma PDX model through … JH Tchaicha, S Lajoie, R Burga, T Ross, B Primack, M Langley, V Young, ... Cancer Research 82 (12_Supplement), LB212-LB212, 2022 | 1 | 2022 |
| Administration of tumor infiltrating lymphocytes with membrane bound interleukin 15 to treat cancer M Khattar, S Subramanian, R Burga, ML Ols, J Ter Meulen, K Pedro, ... US Patent App. 17/577,940, 2022 | | 2022 |
| 166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo R Burga, M Khattar, S Lajoie, K Pedro, C Foley, AV Ocando, J Tremblay, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 3 | 2021 |
| A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models ES Lightcap, P Yu, S Grossman, K Song, M Khattar, K Xega, X He, ... Science translational medicine 13 (611), eaba7791, 2021 | 65 | 2021 |
| 1008P CytoTIL15: A novel TIL therapy for melanoma with superior potency and enhanced persistence without IL2 to improve safety & efficacy and expand patient eligibility M Khattar, R Burga, K Pedro, C Foley, S Lajoie, AV Ocando, J Tremblay, ... Annals of Oncology 32, S852, 2021 | 1 | 2021 |
| cytoTILs (TM) Demonstrate Enhanced In Vivo Persistence in the Absence of IL-2, Paving the Way for Durable Efficacy and Improved Safety in Patients with Solid Tumor Malignancies M Khattar, R Burga, A Storer, C Foley, S Lajoie, D Thornton, S Tam, ... MOLECULAR THERAPY 29 (4), 299-299, 2021 | | 2021 |
| Interleukin 21 (IL-21) regulates chronic allograft vasculopathy (CAV) in murine heart allograft rejection M Khattar, CE Baum, P Schroder, JD Breidenbach, ST Haller, W Chen, ... Plos one 14 (11), e0225624, 2019 | 9 | 2019 |
| TAK-981: A first in class SUMO inhibitor in Phase 1 trials that promotes dendritic cell activation, antigen-presentation, and T cell priming M Khattar, K Song, S Grossman, K Xega, X He, N Idamakanti, D Huszar Cancer research 79 (13_Supplement), 3252-3252, 2019 | 17 | 2019 |
| Abstract lb-294: Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (MAB) in a syngeneic breast cancer model expressing human HER2 T Traore, M Khattar Cancer Research 78 (13_Supplement), LB-294-LB-294, 2018 | 2 | 2018 |
| Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (mAb) in a syngeneic breast cancer model expressing human HER2 M Khattar, T Traore, K Horton, M Gallery, P Brauer, J Riceberg, N Bodyak, ... The Journal of Immunology 200 (1_Supplement), 122.29-122.29, 2018 | 8 | 2018 |
| Agenus’ next generation cancer vaccine platforms M Uduman, M Khattar, B Joshi, A Tanne, B Morin, A Karapetyan, E Drouin, ... Cancer Research 77 (13_Supplement), 4609-4609, 2017 | | 2017 |
| AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model EE Drouin, D Savitsky, AM Gonzalez, R Gombos, D Chand, J Waight, ... Cancer Research 77 (13_Supplement), 3654-3654, 2017 | 4 | 2017 |
| The Agenus Immunogenic Mutation platform (AIM (TM)) generates synthesis-ready blueprints for the AutoSynVax (TM) vaccine patient-specific neoantigen vaccine M Uduman, A Karapetyan, M Khattar, A Tanne, B Morin, J Zelin, S Craig, ... CANCER IMMUNOLOGY RESEARCH 4 (11), 2016 | | 2016 |
| Abstract A028: Pre-clinical development of a first-in-class fully synthetic heat shock protein-based personalized cancer vaccine M Khattar, A Tanne, B Morin, N Wilson, M Uduman, J Zelin, R Stein, ... Cancer Immunology Research 4 (11_Supplement), A028-A028, 2016 | | 2016 |
John C. CastleChief Data Scientist, Monte Rosa Therapeutics在 monterosatx.com 的电子邮件经过验证
